Biomerica Inc. announced that the China National Intellectual Property Administration has issued a Notice of Allowance for a patent application that covers a development stage information technology system that includes an artificial Intelligence (AI) claim aimed at assisting individuals to protect themselves against potential adverse reactions to specific food ingredients. Among other things, the patent claims focus on systems, algorithms and methods to help patients avoid potentially harmful food items based on their unique medical data. The patent encompasses a host of IT methods to evaluate, predict, learn and update the potential health risks associated with consuming specific prepared food items, based on a patient's medical data.

By deriving a confidence level from the patient's health records including a patient’s elevated immune response to specific food ingredients, including those identified through the Biomerica inFoods® IBS test, or other foods that cause adverse reactions such as gluten intolerance, an IT system could be designed to assess the likelihood of an adverse reaction to a common packaged or prepared food that may contain the food ingredient the patient needs to avoid. Leveraging two sets of data, the invention formulates a safety level for each food item in each specific patient. Consequently, a system could be designed to enable an application (App) on a phone, iPad or computer to screen packaged or prepared foods to identify if the packaged or prepared food contains an ingredient previously identified as harmful to the patient.

The technology could also recommend alternative packaged or prepared foods that do not contain the previously identified harmful food ingredient. This patented approach could bridge the gap between healthcare and diet, designed to allow individuals with a variety of medical conditions, allergies, illnesses and food intolerances, whose symptoms are caused or exasperated by consumption of specific food ingredients, to have more control and confidence in their dietary choices. The technology described in this patent that has been issued the notice of allowance can contribute significantly to the digital health sector, ushering in a new era of personalized and preventive healthcare through the power of technology.

This patent further strengthens the Company’s robust intellectual property portfolio in the area of science, diet and technology. This is the second patent on this technology the company has received, the first was issued in Japan.